Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
$11.38
+0.4%
$12.22
$6.25
$19.22
$318.52M0.92260,651 shs351,702 shs
CVRx, Inc. stock logo
CVRX
CVRx
$8.35
-1.2%
$6.37
$4.30
$18.55
$217.71M1.23307,672 shs538,904 shs
Pulmonx Corporation stock logo
LUNG
Pulmonx
$3.09
+6.2%
$3.00
$2.50
$9.37
$124.40M0.45313,927 shs486,731 shs
InspireMD, Inc. stock logo
NSPR
InspireMD
$2.41
+3.0%
$2.40
$1.99
$3.80
$73.83M0.5769,447 shs52,412 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
+1.61%-7.43%-2.33%-7.43%+49.28%
CVRx, Inc. stock logo
CVRX
CVRx
+19.01%+21.41%+43.71%+35.20%-14.73%
Pulmonx Corporation stock logo
LUNG
Pulmonx
+7.78%+6.59%-2.35%-35.62%-63.16%
InspireMD, Inc. stock logo
NSPR
InspireMD
+1.74%-3.70%-4.49%-9.65%-4.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
1.8506 of 5 stars
3.51.00.00.02.40.80.6
CVRx, Inc. stock logo
CVRX
CVRx
3.0804 of 5 stars
3.41.00.00.03.44.20.6
Pulmonx Corporation stock logo
LUNG
Pulmonx
3.4374 of 5 stars
3.35.00.00.02.03.30.6
InspireMD, Inc. stock logo
NSPR
InspireMD
2.8111 of 5 stars
3.53.00.00.01.92.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
3.00
Buy$25.00119.68% Upside
CVRx, Inc. stock logo
CVRX
CVRx
2.86
Moderate Buy$14.5073.65% Upside
Pulmonx Corporation stock logo
LUNG
Pulmonx
2.63
Moderate Buy$11.53272.98% Upside
InspireMD, Inc. stock logo
NSPR
InspireMD
3.00
Buy$4.5086.72% Upside

Current Analyst Ratings Breakdown

Latest NSPR, CLPT, CVRX, and LUNG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/7/2025
CVRx, Inc. stock logo
CVRX
CVRx
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/22/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.15
5/12/2025
InspireMD, Inc. stock logo
NSPR
InspireMD
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$4.50 ➝ $4.00
5/9/2025
CVRx, Inc. stock logo
CVRX
CVRx
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$20.00 ➝ $12.00
5/9/2025
CVRx, Inc. stock logo
CVRX
CVRx
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Underweight$15.00 ➝ $7.00
5/1/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $15.00
5/1/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.00
5/1/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
$32.24M9.88N/AN/A$0.92 per share12.37
CVRx, Inc. stock logo
CVRX
CVRx
$52.87M4.12N/AN/A$2.93 per share2.85
Pulmonx Corporation stock logo
LUNG
Pulmonx
$83.79M1.48N/AN/A$2.17 per share1.42
InspireMD, Inc. stock logo
NSPR
InspireMD
$7.03M10.51N/AN/A$1.83 per share1.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$18.91M-$0.76N/AN/AN/A-64.51%-78.09%-51.33%8/6/2025 (Estimated)
CVRx, Inc. stock logo
CVRX
CVRx
-$59.97M-$2.18N/AN/AN/A-97.49%-79.04%-42.37%8/4/2025 (Estimated)
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$56.39M-$1.44N/AN/AN/A-65.27%-63.69%-34.94%7/30/2025 (Estimated)
InspireMD, Inc. stock logo
NSPR
InspireMD
-$19.92M-$0.79N/AN/AN/A-413.96%-69.42%-57.68%N/A

Latest NSPR, CLPT, CVRX, and LUNG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$0.20N/AN/AN/A$9.20 millionN/A
8/4/2025Q2 2025
CVRx, Inc. stock logo
CVRX
CVRx
-$0.52N/AN/AN/AN/AN/A
7/30/2025Q2 2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$0.40N/AN/AN/A$23.46 millionN/A
5/13/2025Q1 2025
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$0.15-$0.22-$0.07-$0.22$8.21 million$8.49 million
5/8/2025Q1 2025
CVRx, Inc. stock logo
CVRX
CVRx
-$0.56-$0.53+$0.03-$0.53$14.68 million$12.35 million
5/7/2025Q1 2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
N/AN/AN/AN/AN/A
CVRx, Inc. stock logo
CVRX
CVRx
N/AN/AN/AN/AN/A
Pulmonx Corporation stock logo
LUNG
Pulmonx
N/AN/AN/AN/AN/A
InspireMD, Inc. stock logo
NSPR
InspireMD
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
N/A
3.53
2.57
CVRx, Inc. stock logo
CVRX
CVRx
0.71
14.82
13.45
Pulmonx Corporation stock logo
LUNG
Pulmonx
0.38
4.97
4.29
InspireMD, Inc. stock logo
NSPR
InspireMD
N/A
6.39
6.05

Institutional Ownership

CompanyInstitutional Ownership
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
30.08%
CVRx, Inc. stock logo
CVRX
CVRx
75.27%
Pulmonx Corporation stock logo
LUNG
Pulmonx
91.04%
InspireMD, Inc. stock logo
NSPR
InspireMD
44.78%

Insider Ownership

CompanyInsider Ownership
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
6.97%
CVRx, Inc. stock logo
CVRX
CVRx
13.90%
Pulmonx Corporation stock logo
LUNG
Pulmonx
6.80%
InspireMD, Inc. stock logo
NSPR
InspireMD
34.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
11027.99 million26.04 millionOptionable
CVRx, Inc. stock logo
CVRX
CVRx
16026.07 million22.45 millionOptionable
Pulmonx Corporation stock logo
LUNG
Pulmonx
25040.26 million37.52 millionOptionable
InspireMD, Inc. stock logo
NSPR
InspireMD
5030.64 million18.33 millionOptionable

Recent News About These Companies

InspireMD wins CE Mark approval for CGuard Prime
InspireMD Hires New Financial Chief
InspireMD appoints Michael Lawless CFO

New MarketBeat Followers Over Time

Media Sentiment Over Time

ClearPoint Neuro stock logo

ClearPoint Neuro NASDAQ:CLPT

$11.38 +0.05 (+0.44%)
Closing price 04:00 PM Eastern
Extended Trading
$11.42 +0.04 (+0.35%)
As of 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

CVRx stock logo

CVRx NASDAQ:CVRX

$8.35 -0.10 (-1.18%)
Closing price 04:00 PM Eastern
Extended Trading
$8.36 +0.01 (+0.06%)
As of 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Pulmonx stock logo

Pulmonx NASDAQ:LUNG

$3.09 +0.18 (+6.19%)
Closing price 04:00 PM Eastern
Extended Trading
$3.12 +0.03 (+0.97%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

InspireMD stock logo

InspireMD NYSE:NSPR

$2.41 +0.07 (+2.99%)
Closing price 04:00 PM Eastern
Extended Trading
$2.42 +0.01 (+0.41%)
As of 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.